"Human papillomavirus 16" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A type of ALPHAPAPILLOMAVIRUS especially associated with malignant tumors of the CERVIX and the RESPIRATORY MUCOSA.
| Descriptor ID |
D052162
|
| MeSH Number(s) |
B04.280.210.655.050.616 B04.613.204.655.050.616
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Human papillomavirus 16".
Below are MeSH descriptors whose meaning is more specific than "Human papillomavirus 16".
This graph shows the total number of publications written about "Human papillomavirus 16" by people in this website by year, and whether "Human papillomavirus 16" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 1 | 3 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 2 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Human papillomavirus 16" by people in Profiles.
-
The HPV16 E6, E7/miR-23b-3p/ICAT signaling axis promotes proliferation, migration, invasion and EMT of cervical cancer cells. Carcinogenesis. 2023 05 27; 44(3):221-231.
-
Social networks, high-risk anal HPV and coinfection with HIV in young sexual minority men. Sex Transm Infect. 2022 12; 98(8):557-563.
-
Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis. Cancer. 2021 03 15; 127(6):850-864.
-
Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. Carcinogenesis. 2020 11 13; 41(11):1605-1615.
-
A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 07 01; 107(3):487-498.
-
HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. Cancer Res. 2020 02 15; 80(4):732-746.
-
Heterogeneity in the clinical presentation, diagnosis, and treatment initiation of p16-positive oropharyngeal cancer. Am J Otolaryngol. 2019 Sep - Oct; 40(5):626-630.
-
Serum antibodies open the door to prediction and prognostication in human papillomavirus-related head and neck cancer. Cancer. 2017 11 15; 123(22):4310-4313.
-
Integrated genomic and molecular characterization of cervical cancer. Nature. 2017 03 16; 543(7645):378-384.
-
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017 Feb 10; 35(5):490-497.